Tartus, 13 abr (SANA) El Centro Cultural Árabe de Tartus, ciudad costera del oeste de Siria, fue escenario de la velada musical “Armonía”, un recital de piano ...

Moderna CEO Stéphane Bancel’s total compensation remained remarkably stable last year at $19.9 million, even as the vaccines company navigated a “challenging regulatory and business environment.” ...

The currently untitled musical film will be directed by Turning Red's Domee Shi, and is one of three new projects revealed in the report. The other two newly revealed projects mentioned by WSJ are a ...

Please know that I say this as a committed and lifelong lover of musical theater, but adapting any story into a musical rarely makes that story less hokey, no? In the case of “The Notebook,” a musical ...

Moderna MRNA.O has agreed to pay Genevant Sciences, a subsidiary of Roivant Sciences ROIV.O, and Arbutus Biopharma ABUS.O up to $2.25 billion to settle a long-running legal fight over the technology ...

Moderna MRNA-7.49%decrease; red down pointing triangle will pay $950 million to settle patent litigation by Arbutus Biopharma and Genevant Sciences GmbH. The vaccine maker said Tuesday that, as part ...

He sings, he dances, he assassinates. A provocative new musical comedy about the alleged UnitedHealthcare CEO gunman Luigi Mangione is headed to New York City — the real-life setting of the shocking ...

The European Medicines Agency (EMA) announced Friday it has recommended Moderna’s combined mRNA COVID-19 and flu vaccine be granted market authorization in the European Union, marking the first time ...

Both musicals and horror are tried and true genres in the film world. The best horror movies are known for their massive box office appeal, while a number of movie musicals have won Best Picture over ...

Moderna helped to rapidly create vaccines for COVID-19, leading to a financial windfall. But those vaccine sales have waned, and so has the company's top line. There are opportunities ahead for ...

Moderna researchers at work in the company’s lab. The FDA’s reversal of its earlier refusal to review mRNA-1010, the seasonal flu vaccine being developed by Moderna accelerated a revival of its shares ...

The Food and Drug Administration reversed an earlier decision to not review Moderna's flu vaccine and will evaluate the company's modified application for a potential approval, Moderna said on Feb. 18 ...